Core Viewpoint - Farmers & Merchants Bancorp has amended the record date for its fourth quarter dividend while maintaining the declared amount and pay date, reflecting a year-to-date increase in cash dividends per share compared to the previous year [1] Group 1: Dividend Information - The record date for the fourth quarter dividend has been changed from December 15, 2025, to December 4, 2025, with a cash dividend of $5.05 per share and a pay date of January 2, 2026, remaining unchanged [1] - Total year-to-date cash dividends per share declared is $19.35, which is a 6.9% increase from $18.10 per share in 2024 [1][3] Group 2: Company Overview - Farmers & Merchants Bancorp, trading on OTCQX under the symbol FMCB, is the parent company of Farmers & Merchants Bank of Central California, founded in 1916, with $5.6 billion in assets [2] - The bank has maintained a 5-Star rating from BauerFinancial for 35 consecutive years, making it one of the safest banks in the nation [2] Group 3: Dividend History and Recognition - Farmers & Merchants Bancorp has paid dividends for 90 consecutive years and has increased dividends for 60 consecutive years, qualifying as a "Dividend King" [3] - The company ranks 17th among 55 publicly traded "Dividend Kings" based on consecutive years of dividend increases [3] Group 4: Performance Rankings - In July 2025, Farmers & Merchants Bancorp was ranked the 3 best-performing bank in the nation across all asset categories by Bank Director's Magazine [4] - The bank was previously ranked 2 in July 2024 and 1 in July 2023 in the same study [4] Group 5: Industry Position - F&M Bank is the 19th largest bank lender to agriculture in the United States, operating in key agricultural regions of California [8][9] - The bank is dedicated to supporting agribusiness and has been recognized for its contributions to the agricultural community [9]

Core Insights - Eos Energy Enterprises has successfully closed a convertible senior notes offering and a common stock offering, raising approximately $580.5 million and $458.2 million respectively, significantly strengthening its balance sheet [1][2][3] - The financing will enhance Eos' manufacturing capabilities and support its commercial pipeline, which has reached $22.6 billion, indicating strong demand for long-duration energy storage solutions [3][4] - The company aims to capitalize on the growing energy supercycle and position itself as a leader in the long-duration energy storage market [5] Financing Details - The convertible senior notes have a 1.75% interest rate and are due in 2031, with a total principal amount of $600 million issued [1] - The common stock offering involved 35,855,647 shares sold at $12.78 per share [2] - Proceeds from the offerings will be used to retire $200 million of 6.75% convertible senior notes due 2030 and to enhance liquidity by adding approximately $474 million to the balance sheet [8][9] Strategic Implications - The refinancing will lower Eos' cost of capital and interest expenses, providing the liquidity necessary for operational growth and U.S.-based production [4] - The company has issued a warrant to the U.S. Department of Energy for up to 570,000 shares, allowing for potential equity upside as Eos scales its business [6] - The successful financing and oversubscription reflect strong investor confidence in Eos' market potential and strategic direction [3][4]

Core Insights - WillScot Holdings Corporation is a leader in innovative temporary space solutions and will participate in upcoming investor conferences [1][4] Company Overview - WillScot is listed on the Nasdaq under the ticker symbol "WSC" and is the premier provider of turnkey space solutions in North America [2] - The company offers a comprehensive range of products including modular office complexes, mobile offices, classrooms, temporary restrooms, portable storage containers, protective buildings, climate-controlled units, and clearspan structures [2] - WillScot operates from approximately 260 branch locations and additional drop lots across the United States, Canada, and Mexico, serving diverse customer segments across all sectors of the economy [2]

Core Points - Rocket Lab Corporation announced the launch window for the first of two dedicated Electron launches with the Japan Aerospace Exploration Agency (JAXA) [1][3] - The mission, named "RAISE And Shine," is set to launch on December 5, 2025, from Rocket Lab Launch Complex 1 in New Zealand, deploying the RApid Innovative payload demonstration SatellitE-4 (RAISE-4) spacecraft [2][4] - This mission is part of JAXA's Innovative Satellite Technology Demonstration Program, aimed at showcasing new technologies developed by Japan's space economy [3] - The upcoming launch will mark Rocket Lab's 19th launch in 2025, continuing its record of dedicated launches in a single year [4] Company Overview - Rocket Lab is a leading space company providing launch services, spacecraft, payloads, and satellite components for commercial, government, and national security markets [5] - The Electron rocket is recognized as the world's most frequently launched orbital small rocket, with increasing demand for dedicated launches for small satellites [4][5] - Rocket Lab's capabilities include the HASTE rocket for hypersonic test launches and the Neutron launch vehicle currently in development for medium launch needs [5]

Core Insights - Eton Pharmaceuticals is set to participate in the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025, at 9:30 AM ET in New York City [1] Company Overview - Eton Pharmaceuticals focuses on developing and commercializing treatments for rare diseases, currently offering eight commercial products [2] - The company's commercial rare disease products include KHINDIVI™, INCRELEX, ALKINDI SPRINKLE, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone [2] - Eton has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800, and ZENEO hydrocortisone autoinjector [2]

SPRINGFIELD, Mo., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Paul Mueller Company (OTC: MUEL) today announced that the tender offer, announced on October 24, 2025, expired on November 21, 2025, with 31,000 shares being tendered for a total of $15,035,000. On November 25, 2025, Computershare, the Depository for the tender offer, will deliver funds to the Depository Trust Company to be disbursed to the brokerage accounts of those who tendered shares. Also, Computershare will mail checks to those registered shareholder ...

LOS ANGELES, Nov. 24, 2025 (GLOBE NEWSWIRE) -- XMax Inc., a Nevada corporation (“XMax” or the “Company”) (NASDAQ: XWIN) today announced that on November 18, 2025, it entered into a Convertible Promissory Note Purchase Agreement with Billiongold Holding Limited, pursuant to which the Company issued a convertible promissory note in the principal amount of US$5,000,000. The note matures 36 months after funding, bears interest at 6% per annum, and is convertible at the holder’s option into shares of the Company ...

Core Insights - StoneX Group Inc. reported record fiscal year results with net income of $305.9 million, a 17% increase year-over-year, and quarterly net operating revenues of $585.1 million, up 29% [1][2] - The company achieved a record quarterly net income of $85.7 million, with a quarterly return on equity (ROE) of 15.2% [1][2] - The strong performance was attributed to growth in equities trading, prime brokerage, and fixed income, alongside the successful acquisitions of R.J. O'Brien and The Benchmark Company, LLC [2][3] Financial Performance - For the fiscal year ended September 30, 2025, total revenues reached $132.4 billion, a 33% increase from $99.9 billion in the previous year [5] - Quarterly net operating revenues increased to $585.1 million from $454.8 million, marking a 29% rise [26] - The company reported a diluted earnings per share (EPS) of $1.57 for the quarter and $5.89 for the fiscal year, reflecting increases of 1% and 11% respectively [1][5] Revenue Breakdown - Operating revenues from listed derivatives increased by 76% to $207.6 million for the quarter, driven by the acquisition of R.J. O'Brien [13][17] - Securities transactions saw a revenue increase of 26% to $519.4 million, supported by a 25% rise in average daily volume [19][20] - Operating revenues from physical contracts rose by 24% to $65.9 million, primarily due to increased agricultural and energy revenues [21] Segment Performance - The Commercial segment reported revenues of $31.8 billion for the fiscal year, a 33% increase, while the Institutional segment's revenues grew by 27% to $2.5 billion [33] - The Self-Directed/Retail segment experienced a decline in quarterly revenues by 22% to $81.1 million, although it saw a slight annual increase of 4% [9][10] - Payments segment revenues increased by 7% to $52.1 million for the quarter, with a 2% annual growth [9][10] Cost and Expense Analysis - Total interest expense for the quarter was $436.3 million, a 29% increase from the previous year, primarily due to growth in the securities repo and lending businesses [23][24] - Variable compensation and benefits increased by 52% to $183.2 million for the quarter, reflecting the company's growth [27] - Total non-variable expenses were reported at $293.8 million, accounting for 45% of total expenses, compared to 49% in the previous year [27] Strategic Outlook - The company aims to enhance its product offerings and client base through the integration of recent acquisitions, focusing on expanding geographic reach and maintaining high client service standards [3][2] - The acquisition of R.J. O'Brien is expected to significantly contribute to future revenue growth, with an incremental $5.6 billion in average client equity post-acquisition [22][17]

Core Insights - iBio, Inc. will participate in the 8th Annual Evercore Healthcare Conference from December 2-4, 2025, in Miami, highlighting its focus on advancing its next-generation obesity pipeline [1][2]. Company Overview - iBio is an AI-driven biotech company specializing in precision antibody therapies for cardiometabolic diseases, obesity, cancer, and other challenging conditions [4]. - The company utilizes proprietary 3D modeling and innovative drug discovery platforms to develop breakthrough antibody treatments aimed at significant unmet medical needs [4]. Key Events - Martin Brenner, CEO and Chief Scientific Officer of iBio, will engage in a fireside chat on December 4, 2025, discussing the promising non-human primate data for IBIO-610, a potential first-in-class Activin E antibody [2]. - Felipe Duran, CFO of iBio, will be available for one-on-one meetings during the conference, providing opportunities for direct engagement with investors [3]. Additional Information - A livestream of the conference will be available, and a replay will be posted on the Investor section of the iBio website [3].

Core Insights - Nanobiotix reported operational updates and financial results for Q3 2025, highlighting advancements in clinical programs and a significant financing milestone [1][3][4] Operational Highlights - The company completed a non-dilutive royalty financing transaction with HCRx valued up to $71 million, including an upfront payment of $50 million and an additional $21 million expected in one year [4][5][6] - Progress was made in the JNJ-1900 (NBTXR3) program, with the completion of the Phase 3 head and neck cancer study sponsorship transfer to Johnson & Johnson and initial data from a Phase 1 esophageal cancer study [3][4][5] - The Curadigm Nanoprimer program is emerging as a long-term growth driver, with new patent applications filed and pre-clinical data presented at industry conferences [5][6] Financial Updates - As of September 30, 2025, the company reported €20.4 million in cash and cash equivalents, with the recent financing expected to extend cash visibility into early 2028 [4][12] - The royalty financing will be repaid from a capped portion of milestones and royalties on sales of JNJ-1900, structured through a trust involving multiple parties [7] Clinical Development Outlook - Clinical updates from ongoing or completed studies of JNJ-1900 (NBTXR3) in various cancers, including melanoma, lung cancer, pancreatic cancer, and esophageal cancer, are expected in 2026 [4][8][12] - JNJ-1900 (NBTXR3) is being evaluated as a single agent and in combination therapies, with a focus on solid tumors treatable with radiotherapy [9][10][11]